Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) is launching Wildflower brand edibles crafted with minor cannabinoids in four flavors that provide a range of experiences to meet various consumer needs, including CBN, CBG and CBD, as well as full spectrum THC Live Rosin.
- Sweet Dreams Blood Orange CBN + CBD +THC Gummies – each of the ten gummies has 1 mg of full spectrum Live Rosin, as well as 1 mg of CBD and 1 mg of CBN.
- Sweet Dreams Goji Berry CBN + CBD +THC Gummies - each of the five gummies has 2 mg of full spectrum Live Rosin, as well as 10 mg of CBD and 10 mg of CBN.
- Sweet Dreams Cherry THC + CBN + CBD Gummies - each of the five gummies has 2 mg of full spectrum Live Rosin, as well as 1 mg of CBD and 1 mg of CBN.
- Daily Bliss Lemon Ginger CBG + CBD Gummies - each of the ten gummies has 10 mg of CBD and 10 mg of CBG.
These gummies contain all-natural ingredients and are made with real fruit purées, with no added sugar or colors and are vegan and gluten-free.
"At Rubicon Organics, we strive to deliver innovative and premium products and these edibles are a significant step to expanding our Wildflower product line-up to offer a range of high-quality, natural gummies," said Melanie Ramsey, chief commercial officer at the Vancouver-based company. "Our entry into the edibles category reflects our commitment to meeting the evolving needs and preferences of our diverse consumer base."
The Blood Orange, Goji Berry and Lemon Ginger Gummies will be available for ordering in British Columbia starting October 2023.
All four flavors will be available in Alberta in November 2023. Ontario will launch the Cherry and Goji Berry flavors in February 2024.
ROMJF Price Action
Rubicon's shares traded 2.4465% lower at $0.319 per share after the market close on Monday.
Related News
- This Pot Stock Significantly Shrinks Its Quarterly Loss, Sees 28% YoY Revenue Growth, Projects Positive Free Cashflow For Full Year
- Rubicon Organics Q1 Revenue Grows 71% YoY, Thanks To Expansion Of 1964 Supply Co, Here Are The Details
- Rubicon Organics FY22 Revenue Grows 57% To $26.4M, What About Adjusted EBITDA?
Photo: Courtesy of Elsa Olofsson on Unsplash